Pharmaceutical Combination of Wnt Signaling and Macc1 Inhibitors

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a pharmaceutical combination therapy that targets two distinct pathways involved in cancer progression and metastasis: the Wnt/β-catenin signaling pathway (particularly by inhibiting S100A4, with agents like niclosamide) and MACC1 (with statins or MEK1 inhibitors). By simultaneously inhibiting both pathways, the combination exhibits a surprising and strong synergistic effect, leading to a more effective reduction in tumor cell movement and metastasis than either approach alone. The invention is particularly relevant to solid tumors (such as colorectal and pancreatic cancers), both for treatment and for preventing metastasis in high-risk patients (especially those with high MACC1 and/or S100A4 levels).

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of patients with solid tumors, especially colorectal or pancreatic cancer, by reducing tumor growth and preventing metastasis.
• Prophylactic therapy for early-stage cancer patients (stage 0, I, II) who exhibit elevated MACC1 and/or S100A4, to prevent metastasis after surgical removal of the primary tumor.
• Adjunct therapy in patients with advanced or metastatic cancers to reduce further tumor spread.
• Stratified or personalized therapy based on biomarker (MACC1/S100A4) levels to identify and treat patients at highest risk of metastasis.
• Combination therapy with existing chemotherapy drugs to synergistically inhibit cancer progression and improve survival rates.

BenefitsContent extracted from patent full text and abstract with AI.

• Synergistic anti-metastatic and anti-proliferative effects greater than the sum of the individual drugs, allowing lower doses and potentially fewer side effects.
• Effective both as therapeutic and prophylactic treatment, enabling intervention even before clinical metastasis occurs.
• Applicable to a wide range of solid tumors, especially those characterized by high MACC1 and S100A4 expression.
• Enables patient stratification for personalized treatment, focusing therapy on high-risk individuals.
• Utilizes well-tolerated, often FDA-approved drugs (statins and niclosamide), potentially speeding up clinical translation.
• Demonstrated efficacy in preclinical models (cell culture and mouse models) for reducing metastasis.
• May be combined with standard chemotherapeutic agents for enhanced efficacy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a pharmaceutical combination, comprising an inhibitor of the Wnt/β-catenin signaling pathway and an inhibitor of MACC1. In preferred embodiments the invention relates to a combination of an inhibitor of S100A4 as a Wnt-signalling inhibitor, preferably niclosamide, and a statin or MEK1 inhibitor as an inhibitor of MACC1. The invention further relates to a pharmaceutical composition comprising the combination, and use of the combination or composition in the treatment of a tumor disease, such as a solid tumor, and/or for the treatment and/or prophylaxis of tumor metastasis.